Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

BACKGROUND: Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Saltarella, Ilaria, Morabito, Fortunato, Giuliani, Nicola, Terragna, Carolina, Omedè, Paola, Palumbo, Antonio, Bringhen, Sara, De Paoli, Lorenzo, Martino, Enrica, Larocca, Alessandra, Offidani, Massimo, Patriarca, Francesca, Nozzoli, Chiara, Guglielmelli, Tommasina, Benevolo, Giulia, Callea, Vincenzo, Baldini, Luca, Grasso, Mariella, Leonardi, Giovanna, Rizzo, Manuela, Falcone, Antonietta Pia, Gottardi, Daniela, Montefusco, Vittorio, Musto, Pellegrino, Petrucci, Maria Teresa, Dammacco, Franco, Boccadoro, Mario, Vacca, Angelo, Ria, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327520/
https://www.ncbi.nlm.nih.gov/pubmed/30626425
http://dx.doi.org/10.1186/s13045-018-0691-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327520/
https://www.ncbi.nlm.nih.gov/pubmed/30626425
http://dx.doi.org/10.1186/s13045-018-0691-4

Ejemplares similares